The research, which focused on adults aged 65 and older and patients with phlebolymphedema, highlights a clear performance gap between the two treatment modalities. In the elderly cohort, those using Dayspring achieved a mean limb volume reduction of 353.9 mL, dwarfing the 10.7 mL reduction seen with standard pneumatic devices. Beyond physical measurements, 86% of patients adhered to their prescribed Dayspring regimen, compared to only 55% for the pneumatic alternative.
Similar trends emerged among patients with phlebolymphedema—a condition stemming from chronic venous insufficiency. Dayspring users experienced a 424.4 mL reduction in limb volume, while pneumatic device users saw a reduction of only 50.8 mL. Dr. Michael Barfield, lead investigator at New York-Presbyterian/Weill Cornell Medical Center, noted that this specific population requires evidence-based interventions due to the complex interaction between venous hypertension and lymphatic dysfunction. Across both study groups, a vast majority of participants—77% of seniors and 85% of phlebolymphedema patients—expressed a clear preference for the Dayspring system, citing improved quality of life and the ability to remain mobile during active therapy.
Comments (0)
No comments yet. Be the first!